Sopharma AD-Sofia (WAR:SPH) LT-Debt-to-Total-Asset : 0.08 (As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Sopharma AD-Sofia LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sopharma AD-Sofia's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.08.

Sopharma AD-Sofia's long-term debt to total assets ratio increased from Jun. 2023 (0.07) to Jun. 2024 (0.08). It may suggest that Sopharma AD-Sofia is progressively becoming more dependent on debt to grow their business.

Sopharma AD-Sofia LT-Debt-to-Total-Asset Historical Data

The historical data trend for Sopharma AD-Sofia's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sopharma AD-Sofia LT-Debt-to-Total-Asset Chart

Sopharma AD-Sofia Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.07

0.06

0.07

Sopharma AD-Sofia Quarterly Data
	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.07	0.08	0.07	0.08	0.08

Sopharma AD-Sofia LT-Debt-to-Total-Asset Calculation

Sopharma AD-Sofia's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	244.078	/	3323.769
	=	0.07

Sopharma AD-Sofia's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	246.967	/	3254.636
	=	0.08

Sopharma AD-Sofia (WAR:SPH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sopharma AD-Sofia LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Sopharma AD-Sofia's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sopharma AD-Sofia Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sopharma AD-Sofia (WAR:SPH) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

SFA:Bulgaria

Address

5 Lachezar Stanchev Street, Sopharma Business Towers, Building A, Floor 11, Sofia, BGR, 1756

Website

https://www.sopharmagroup.com

Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products; and Others. It generates the majority of its revenue from the Distribution of pharmaceutical products.